Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plavix Patent Infringement Trial Set For Jan. 22

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi/Bristol demonstrated that Apotex patent invalidity defense "lacks substantial merit," according to a court ruling granting a preliminary injunction blocking generics.
Advertisement

Related Content

Generic Plavix Supply Is Dwindling, McKesson Says
Plavix "Irreparable Harm" Debated During Preliminary Injunction Appeal
Plavix Sales Plummet With Generic Entry
Apotex Appeal On Plavix Preliminary Injunction Ruling To Begin Oct. 31
Bristol Plans Plavix Price Increase Next Year
Bristol Lowers EPS Guidance On Plavix Decision
Judge Rules Against Plavix Recall Based On Sanofi/Bristol’s Settlement Negotiations
Judge Rules Against Plavix Recall Based On Sanofi/Bristol’s Settlement Negotiations
Plavix Generic Faces Injunction, But Not Recall
Apotex Seeks $4 Bil. Bond From Sanofi/Bristol At Plavix Injunction Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS064830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel